Sionna Therapeutics (NASDAQ:SION) Trading Down 4.2% - What's Next?

Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) traded down 4.2% during mid-day trading on Monday . The stock traded as low as $13.11 and last traded at $13.11. 40,547 shares traded hands during mid-day trading, a decline of 83% from the average session volume of 232,004 shares. The stock had previously closed at $13.69.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. TD Cowen started coverage on Sionna Therapeutics in a research report on Tuesday, March 4th. They set a "buy" rating on the stock. Stifel Nicolaus began coverage on Sionna Therapeutics in a research report on Tuesday, March 4th. They set a "buy" rating and a $32.00 price target on the stock. Finally, Guggenheim started coverage on Sionna Therapeutics in a report on Tuesday, March 4th. They issued a "buy" rating and a $45.00 price objective for the company.

Sionna Therapeutics Price Performance

Sionna Therapeutics (NASDAQ:SION - Get Free Report) last announced its quarterly earnings data on Thursday, March 20th. The company reported ($3.38) EPS for the quarter, missing the consensus estimate of ($2.68) by ($0.70).

About Sionna Therapeutics

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.